ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 675,62
-0,26%
Dow Jones
39 375,87
0,17%
DAX
18 475,45
0,12%
Brent Oil
86,555
-0,89%
Bitcoin
56 327,13
-1,15%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. IDEAYA Biosciences Inc (IDYA)

  7. IDEAYA Biosciences Inc (IDYA) Actualités

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IDYA
DateHeureSourceTitreSymboleSociété
05/07/202422h05PR Newswire (US)IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
28/06/202412h00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
25/06/202412h00PR Newswire (US)IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder CancerNASDAQ:IDYAIDEAYA Biosciences Inc
24/06/202412h00PR Newswire (US)IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
03/06/202412h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
03/06/202412h00PR Newswire (US)IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant StudyNASDAQ:IDYAIDEAYA Biosciences Inc
31/05/202422h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
29/05/202423h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
29/05/202412h00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
28/05/202412h00PR Newswire (US)IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business DevelopmentNASDAQ:IDYAIDEAYA Biosciences Inc
24/05/202403h21PR Newswire (US)/C O R R E C T I O N -- IDEAYA Biosciences, Inc./NASDAQ:IDYAIDEAYA Biosciences Inc
23/05/202423h05PR Newswire (US)IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
07/05/202412h00PR Newswire (US)IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
01/05/202412h00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
24/04/202416h05PR Newswire (US)IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyNASDAQ:IDYAIDEAYA Biosciences Inc
22/04/202412h00PR Newswire (US)IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerNASDAQ:IDYAIDEAYA Biosciences Inc
01/04/202412h00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
12/03/202411h00PR Newswire (US)IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerNASDAQ:IDYAIDEAYA Biosciences Inc
04/03/202412h00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
20/02/202422h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IDYAIDEAYA Biosciences Inc
20/02/202412h00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
14/02/202412h44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IDYAIDEAYA Biosciences Inc
01/02/202412h00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
19/01/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IDYAIDEAYA Biosciences Inc
07/01/202415h00PR Newswire (US)IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate GuidanceNASDAQ:IDYAIDEAYA Biosciences Inc
05/12/202312h00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
04/12/202312h00PR Newswire (US)IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder CancerNASDAQ:IDYAIDEAYA Biosciences Inc
03/12/202315h00PR Newswire (US)IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023NASDAQ:IDYAIDEAYA Biosciences Inc
07/11/202322h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IDYAIDEAYA Biosciences Inc
07/11/202312h00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:IDYA

Dernières Valeurs Consultées

NASDAQ
NVDA
NVIDIA
EU
HO
Thales
EU
MC
Lvmh Moet Hennessy Louis...
EU
PX1
CAC 40
COIN
ETHUSD
Ethereum
EU
CS
Axa
EU
PX4
SBF 120
NYSE
MCD
McDonalds
EU
DG
Vinci
NYSE
KO
Coca Cola
EU
VIV
Vivendi
EU
BNP
BNP Paribas
NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés